About Our Fund:
Synergy Life Science Partners is a venture capital firm that helps to form and invests in early stage medical device and combination product (device with a therapeutic payload such as biologics and drugs) companies. We take a synergistic approach with entrepreneurs to build valuable companies through capital allocation, access to our valuable network and our technical, clinical and operational expertise.
Synergy focuses on early-stage companies in large therapeutic areas. We seek companies with productive, domain-experienced leadership teams who are winners. We target companies with big ideas that are matched with focused, capital efficient, clinically-driven development plans and sound business models. Our diversified experiences allow and enable us to support the management of companies, both technically and operationally, to enable these companies to scale and prosper.
Synergy will invest a portion of its funds in Synecor originated opportunities. Synecor is a highly successful medical incubator founded in 2000 by Richard Stack and Bill Starling, two of Synergys Managing Directors.
Our Investment Criteria:
We will review opportunities that fit within Synergy?s investment criteria. Our investment decision is based primarily on several guiding principles:
- Leadership Teams
We look for teams with relevant domain experience, excellent chemistry, and a history of success.
- Therapeutic Areas of Interest
We focus on large therapeutic areas including: Cardiovascular, Orthopedics and Spine, Ophthalmology, Metabolic: Obesity and Diabetes, Oncology, Gastro-Intestinal Disease and Respiratory Disease.
- Technology Profile
A unique and proprietary product is key. We look for companies with unchallenged intellectual property that possess the ability to maximize the platform potential.
- Regulatory / Clinical Path
The company must have a predictable and capital efficient regulatory and clinical path.
- Cost and Reimbursement Profile
The company must have a compelling health economics story and a well laid out path to procure adequate reimbursement.
We focus on early-stage companies raising their first or second round of venture financing, with proof of concept.
We invest in companies located in the United States.